Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Reilly

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Seminars in Dialysis|August 9, 2006
Anticoagulation and continuous renal replacement therapyJamshid Amanzadeh, Robert F Reilly
Nature Clinical Practice. Nephrology|August 26, 2006
Hypophosphatemia: an evidence-based approach to its clinical consequences and managementJamshid Amanzadeh, Robert F Reilly
Seminars in Dialysis|August 20, 2011
Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation?Venkata Yalamanchili, Robert F Reilly
Nature Clinical Practice. Nephrology|November 23, 2007
What nephrologists need to know about gadoliniumJeffrey G Penfield, Robert F Reilly
Seminars in Dialysis|September 15, 2011
Gadolinium and nephrogenic systemic fibrosis: have we overreacted?Jeffrey G Penfield, Robert F Reilly
Seminars in Dialysis|January 30, 2008
Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney diseaseMark A Perazella, Robert F Reilly
Nature Reviews. Nephrology|September 28, 2011
The mechanism of hypocalciuria with NaCl cotransporter inhibitionRobert F Reilly, Chou-Long Huang
Pediatric Nephrology (Berlin, Germany)|June 17, 2009
Rhabdomyolysis: a review, with emphasis on the pediatric populationEssam F Elsayed, Robert F Reilly
The American Journal of the Medical Sciences|December 9, 2010
Imaging patients with kidney disease: how do we approach contrast-related toxicity?Mark A Perazella, Robert F Reilly
Seminars in Dialysis|January 30, 2008
Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?Jeffrey G Penfield, Robert F Reilly
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Seminars in Dialysis|August 9, 2006
Anticoagulation and continuous renal replacement therapyJamshid Amanzadeh, Robert F Reilly
Nature Clinical Practice. Nephrology|August 26, 2006
Hypophosphatemia: an evidence-based approach to its clinical consequences and managementJamshid Amanzadeh, Robert F Reilly
Seminars in Dialysis|August 20, 2011
Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation?Venkata Yalamanchili, Robert F Reilly
Nature Clinical Practice. Nephrology|November 23, 2007
What nephrologists need to know about gadoliniumJeffrey G Penfield, Robert F Reilly
Seminars in Dialysis|September 15, 2011
Gadolinium and nephrogenic systemic fibrosis: have we overreacted?Jeffrey G Penfield, Robert F Reilly
Seminars in Dialysis|January 30, 2008
Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney diseaseMark A Perazella, Robert F Reilly
Nature Reviews. Nephrology|September 28, 2011
The mechanism of hypocalciuria with NaCl cotransporter inhibitionRobert F Reilly, Chou-Long Huang
Pediatric Nephrology (Berlin, Germany)|June 17, 2009
Rhabdomyolysis: a review, with emphasis on the pediatric populationEssam F Elsayed, Robert F Reilly
The American Journal of the Medical Sciences|December 9, 2010
Imaging patients with kidney disease: how do we approach contrast-related toxicity?Mark A Perazella, Robert F Reilly
Seminars in Dialysis|January 30, 2008
Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?Jeffrey G Penfield, Robert F Reilly
Pageof 5